SCHEMBL898593

SCHEMBL898593

CN(C)/C=C1/CC2(C=CC1=O)CCN(C(=O)O)CC2

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL898594 1.00
SCHEMBL12663837 0.83 KDM4E (0.32)
SCHEMBL899392 0.83 USP2 (0.35)
SCHEMBL899390 0.83 USP2 (0.35)
SCHEMBL899389 0.83 USP2 (0.35)
SCHEMBL899156 0.80 MEN1 (0.44)
SCHEMBL16835486 0.74 DDB1 (0.31)
SCHEMBL4052256 0.72 CYP2D6 (0.31)
SCHEMBL4052259 0.72 CYP2D6 (0.31)
SCHEMBL1622835 0.69 SMARCA4 (0.34)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230405002-A1 COMBINATIONS OF DIACYLGLYCEROL ACYLTRANSFERASE 2 INHIBITORS AND ACETYL-COA CARBOXYLASE INHIBITOR PFIZER INC. (US) 2023-12-21 US disclosed
US-20230322777-A1 N1-Pyrazolospiroketone Acetyl-CoA Carboxylase Inhibitors PFIZER INC. (US) 2023-10-12 US disclosed
US-20230218616-A1 Combinations for Treatment of NAFLD/NASH and Related Diseases PFIZER INC. (US) 2023-07-13 US disclosed
US-11673890-B2 N1-pyrazolospiroketone acetyl-CoA carboxylase inhibitors PFIZER INC. (US) 2023-06-13 US disclosed
EP-3713942-B1 CRYSTALLINE 2-AMINO-2-(HYDROXYMETHYL)PROPANE-1,3-DIOL SALT OF 4-(4-(1-ISOPROPYL-7-OXO-1,4,6,7-TETRAHYDROSPIRO[INDAZOLE-5,4'-PIPERIDINE]-1'-CARBONYL)-6-METHOXYPYRIDIN-2-YL)BENZOIC ACID PFIZER (US) 2023-03-08 EP disclosed
EP-4110395-A1 COMBINATIONS FOR TREATMENT OF NAFLD/NASH AND RELATED DISEASES Pfizer Inc. (US) 2023-01-04 EP disclosed
US-20220387402-A1 COMBINATIONS COMPRISING BENZODIOXOL AS GLP-1R AGONISTS FOR USE IN THE TREATMENT OF NASH/NAFLD AND RELATED DISEASES PFIZER INC. (US) 2022-12-08 US disclosed
US-11325909-B2 Crystalline 2-amino-2-(hydroxymethyl)propane-1,3-diol salt of 4-(4-(1-isopropyl-7-OXO-1,4,6,7-tetrahydrospiro[indazole-5,4′-piperidine]-1′-carbonyl)-6-methoxypryridin-2-YL)benzoic acid PFIZER INC. (US) 2022-05-10 US disclosed
US-11254660-B2 Combinations for treatment of NASH/NAFLD and related diseases PFIZER INC. (US) 2022-02-22 US disclosed
US-20220023299-A1 Combinations For Treatment Of NASH/NAFLD And Related Diseases PFIZER INC. (US) 2022-01-27 US disclosed
US-9908883-B2 N1-pyrazolospiroketone acetyl-CoA carboxylase inhibitors PFIZER INC. (US) 2018-03-06 US disclosed
US-20160347752-A1 N1-PYRAZOLOSPIROKETONE ACETYL-CoA CARBOXYLASE INHIBITORS PFIZER INC. (US) 2016-12-01 US disclosed
EP-2621493-B1 N1-PYRAZOLOSPIROKETONE ACETYL-CoA CARBOXYLASE INHIBITORS PFIZER (US) 2016-08-17 EP disclosed
US-20150376185-A1 N1-PYRAZOLOSPIROKETONE ACETYL-CoA CARBOXYLASE INHIBITORS PFIZER INC. (US) 2015-12-31 US disclosed
US-9145416-B2 N1-pyrazolospiroketone acetyl-CoA carboxylase inhibitors PFIZER INC. (US) 2015-09-29 US disclosed
US-20150011470-A1 N1-PYRAZOLOSPIROKETONE ACETYL-CoA CARBOXYLASE INHIBITORS PFIZER INC. (US) 2015-01-08 US disclosed
US-8859577-B2 N1-pyrazolospiroketone acetyl-CoA carboxylase inhibitors PFIZER INC. (US) 2014-10-14 US disclosed
EP-2621493-A1 N1-PYRAZOLOSPIROKETONE ACETYL-CoA CARBOXYLASE INHIBITORS Pfizer Inc (US) 2013-08-07 EP disclosed
US-20130190334-A1 N1-PYRAZOLOSPIROKETONE ACETYL-CoA CARBOXYLASE INHIBITORS PFIZER INC. (US) 2013-07-25 US disclosed
WO-2012042433-A1 N1-PYRAZOLOSPIROKETONE ACETYL-CoA CARBOXYLASE INHIBITORS PFIZER INC. (US) 2012-04-05 WO disclosed